Literature DB >> 9748360

Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).

M J Robins1, S F Wnuk, X Yang, C S Yuan, R T Borchardt, J Balzarini, E De Clercq.   

Abstract

Treatment of a protected 9-(5, 6-dideoxy-beta-D-ribo-hex-5-ynofuranosyl)adenine derivative with silver nitrate and N-iodosuccinimide (NIS) and deprotection gave the 6'-iodo acetylenic nucleoside analogue 3c. Halogenation of 3-O-benzoyl-5,6-dideoxy-1, 2-O-isopropylidene-alpha-D-ribo-hex-5-enofuranose gave 6-halo acetylenic sugars that were converted to anomeric 1,2-di-O-acetyl derivatives and coupled with 6-N-benzoyladenine. These intermediates were deprotected to give the 6'-chloro 3a, 6'-bromo 3b, and 6'-iodo 3c acetylenic nucleoside analogues. Iodo compound 3c appears to inactivate S-adenosyl-L-homocysteine hydrolase by a type I ("cofactor depletion") mechanism since complete reduction of enzyme-bound NAD+ to NADH was observed and no release of adenine or iodide ion was detected. In contrast, incubation of the enzyme with the chloro 3a or bromo 3b analogues resulted in release of Cl- or Br- and Ade, as well as partial reduction of E-NAD+ to E-NADH. Compounds 3a, 3b, and 3c were inhibitory to replication of vaccinia virus, vesicular stomatitis virus, parainfluenza-3 virus, and reovirus-1 (3a < 3b < 3c, in order of increasing activity). The antiviral effects appear to correlate with type I mechanism-based inhibition of S-adenosyl-L-homocysteine hydrolase. Mechanistic considerations are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748360     DOI: 10.1021/jm980163m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  The rationale for targeting the NAD/NADH cofactor binding site of parasitic S-adenosyl-L-homocysteine hydrolase for the design of anti-parasitic drugs.

Authors:  Sumin Cai; Qing-Shan Li; Jianwen Fang; Ronald T Borchardt; Krzysztof Kuczera; C Russell Middaugh; Richard L Schowen
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2009-05       Impact factor: 1.381

Review 2.  Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

3.  Synthesis of 5'-functionalized nucleosides: S-Adenosylhomocysteine analogues with the carbon-5' and sulfur atoms replaced by a vinyl or halovinyl unit.

Authors:  Stanislaw F Wnuk; Pablo R Sacasa; Elzbieta Lewandowska; Daniela Andrei; Sumin Cai; Ronald T Borchardt
Journal:  Bioorg Med Chem       Date:  2008-04-12       Impact factor: 3.641

4.  Mycophenolic acid inhibits replication of Type 2 Winnipeg, a cerebrospinal fluid-derived reovirus isolate.

Authors:  Laura L Hermann; Kevin M Coombs
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-09       Impact factor: 2.471

5.  S-Ribosylhomocysteine analogues with the carbon-5 and sulfur atoms replaced by a vinyl or (fluoro)vinyl unit.

Authors:  Stanislaw F Wnuk; Jennifer Lalama; Craig A Garmendia; Jenay Robert; Jinge Zhu; Dehua Pei
Journal:  Bioorg Med Chem       Date:  2008-03-14       Impact factor: 3.641

6.  Inhibition of reovirus by mycophenolic acid is associated with the M1 genome segment.

Authors:  Laura L Hermann; Kevin M Coombs
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.